NRL will underscore its leadership in specialized pathology and molecular diagnostics, supporting precise disease classification and evidence-based therapeutic decisions.
NRL’s extensive portfolio—encompassing immunohistochemistry, tumor biomarker profiling, HER2 and hormone receptor analysis, and genomic testing—demonstrates its commitment to advancing diagnostic accuracy.
Register NowNRL’s extensive portfolio—encompassing immunohistochemistry, tumor biomarker profiling, HER2 and hormone receptor analysis, and genomic testing—demonstrates its commitment to advancing diagnostic accuracy.
Through this global exchange of expertise, NRL continues to champion innovation, collaboration, and excellence in breast pathology and cancer diagnostics across the region.
Details
| Date | 17 January, 2026 |
| Timing | 8:00 PM to 5:00 PM |
| Audience | Medical professionals specializing in pathology, breast oncology, and diagnostic research |
| Venue | Cleveland Clinic Abu Dhabi |
| Registration Link | Click Here |
| Accreditation | DOH CME Accreditation under process |
